Rankings
▼
Calendar
EBS FY 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$433M
FY 2019 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$1.1B
+41.4% YoY
Gross Profit
$483M
43.7% margin
Operating Income
$114M
10.3% margin
Net Income
$55M
4.9% margin
EPS (Diluted)
$1.04
Cash Flow
Operating Cash Flow
$188M
Free Cash Flow
$101M
Stock-Based Comp.
$27M
Balance Sheet
Total Assets
$2.3B
Total Liabilities
$1.2B
Stockholders' Equity
$1.1B
Cash & Equivalents
$168M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.1B
$782M
+41.4%
Gross Profit
$483M
$320M
+50.8%
Operating Income
$114M
$90M
+27.1%
Net Income
$55M
$63M
-13.1%
← Q4 2018
All Quarters
Q1 2019 →